{"id":61961,"date":"2025-10-02T07:02:41","date_gmt":"2025-10-02T05:02:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/"},"modified":"2025-10-02T07:02:41","modified_gmt":"2025-10-02T05:02:41","slug":"leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/","title":{"rendered":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Dutch biotech Leyden Labs has raised a \u20ac30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company\u2019s other mucosal pipeline and platform activities.<\/i><\/li>\n<li>\n<i>The support from the EIC Fund and Invest-NL helps strengthen Europe\u2019s preparedness against current and future viral threats.<\/i><\/li>\n<li>\n<i>This strategic investment further builds out the global syndicate of investors in Leyden Labs, now with representation by US, Asian and European investors.<\/i><\/li>\n<\/ul>\n<p>\n\u00a0<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/4\/Leyden_Labs.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/4\/Leyden_Labs.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/21\/Leyden_Labs.jpg\"><\/a><\/p>\n<p>LEIDEN, the Netherlands&#8211;(BUSINESS WIRE)&#8211;Dutch biotech Leyden Laboratories B.V. (the \u201cCompany\u201d or \u201cLeyden Labs\u201d) today announced \u20ac30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL to advance the Company\u2019s clinical development of its pan-influenza nasal spray (PanFlu) and broader mucosal pipeline and platform activities.<\/p>\n<p>\n<b>A novel approach to respiratory virus protection<\/b><\/p>\n<p>\nLeyden Labs is developing nasal sprays that block airborne respiratory viruses at their point of entry. By delivering broadly protective antibodies directly to the respiratory mucosa, this approach provides immediate protection where infections begin. Unlike traditional vaccines, which depend on systemic immune responses, these antibody-based nasal sprays have the potential to protect everyone, even those with weakened immune systems. Furthermore, they are designed to target the most conserved regions of viruses so they will remain effective even as viruses mutate.<\/p>\n<p>\n<b>Preparing Europe for future pandemics and reducing the burden of seasonal infections<\/b><\/p>\n<p>\n\u201cThe COVID-19 pandemic has underlined the critical importance of Europe\u2019s preparedness for future health crises. With EIC Fund\u2019s investment in Leyden Labs, we are backing pioneering science and innovative approaches to combat respiratory viruses,\u201d said <b>Svetoslava Georgieva<\/b>, Chair of the EIC Fund Board.<\/p>\n<p>\n\u201cAs the Dutch national promotional institution, we are proud to support Leyden Labs in its mission to stop respiratory viruses at the gate with a preventive, easy-to-use nasal spray. With unique science at its core, this company addresses a limitation of vaccines, protecting vulnerable groups such as the elderly and immunocompromised via nasal spray, especially during flu season or even pandemics. This investment strengthens Europe\u2019s resilience and autonomy in health innovation,\u201d said <b>Ineke Cazander<\/b>, investment principal at Invest-NL.<\/p>\n<p>\n<b>Strengthening the global investor base<\/b><\/p>\n<p>\n\u201cWith PanFlu, we are taking a bold step to stop influenza viruses at the gate. We are proud to welcome these two esteemed European funds, each with the goal of accelerating innovations in Europe that deliver public benefit. Their support for our strategy to develop novel products to protect against respiratory viruses is a wonderful endorsement of our relentless efforts,\u201d said <b>Koenraad Wiedhaup<\/b>, co-founder and CEO of Leyden Labs.<\/p>\n<p>\n\u201cThese latest investments build on the significant momentum in our fundraising efforts this year, including our <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fleydenlabs.com%2F20240006-news-item-leyden-labs-raises-70m-to-advance-its-intranasal-antibody-programs&amp;esheet=54332409&amp;newsitemid=20251001741614&amp;lan=en-US&amp;anchor=%2470+million&amp;index=1&amp;md5=60a535fcb62f278b2f343c75ce23b064\" rel=\"nofollow\" shape=\"rect\">$70 million<\/a> Series B announced in January and recent <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fleydenlabs.com%2F20250002-news-item-leyden-labs-lands-e20-million-eib-investment-facilitated-by-hera&amp;esheet=54332409&amp;newsitemid=20251001741614&amp;lan=en-US&amp;anchor=%26%238364%3B20+million&amp;index=2&amp;md5=ed1069b85fb0ac35d7e296ebaec2ef65\" rel=\"nofollow\" shape=\"rect\">\u20ac20 million<\/a> EIB venture debt investment facilitated by the European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response Authority (HERA),\u201d said <b>Marieke van der Lans<\/b>, CFO of Leyden Labs.<\/p>\n<p>\nNow with investors from the US, Asia, and Europe, Leyden Labs can even more greatly benefit from diverse perspectives that shape its strategy and create new opportunities to address global needs for protection against seasonal and pandemic respiratory viruses.<\/p>\n<p>\n<b>Scientific evidence underlines broad potential of PanFlu nasal spray<\/b><\/p>\n<p>\nThe antibody component of PanFlu, CR9114, is the most widely protective influenza antibody identified so far worldwide. It uniquely recognizes the wide diversity of flu viruses that exist. This observation makes the antibody highly promising to defend against all types of the flu, even those that have not yet emerged. Applying unique insights about the biology of the respiratory mucosa to research and clinical development activities, the Leyden Labs team is working to demonstrate that this powerful antibody can be highly effective in the respiratory tract to combat infections.<\/p>\n<p>\n<b>About Leyden Laboratories B.V.<\/b><\/p>\n<p>\nLeyden Laboratories B.V. (Leyden Labs), founded in 2020, is a clinical-stage biotechnology company based in the Netherlands. Leyden Labs is working to free people from the threat of respiratory viruses by leveraging its Mucosal Protection Platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. Leyden Labs is supported by a strong syndicate of investors and ambassadors; VC investors include GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio (a life sciences venture investor established by Temasek), Polaris Partners, Qiming Venture Partners, Invus, SoftBank Vision Fund 2, Byers Capital \/ Brook Byers and Bluebird Ventures. The company also received financing from the European Investment Bank, guaranteed by European Commission\u2019s InvestEU initiative through its Health Emergency Preparedness and Response (HERA). To learn more, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.leydenlabs.com&amp;esheet=54332409&amp;newsitemid=20251001741614&amp;lan=en-US&amp;anchor=www.leydenlabs.com&amp;index=3&amp;md5=5ffd6f5704aa9fbb88f903af8ca9a2e4\" rel=\"nofollow\" shape=\"rect\">www.leydenlabs.com<\/a>.<\/p>\n<p>\nCR9114, Leyden Labs\u2019 lead product candidate for the PanFlu program, is a human monoclonal antibody that protects against influenza in preclinical models. Leyden Labs holds an exclusive license from Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize CR9114.<\/p>\n<p>\n<b>About European Innovation Council Fund<\/b><\/p>\n<p>\nThe European Innovation Council Fund from the European Commission is a deep tech investor across all technologies. The EIC Fund aims to fill a critical financing gap, to support companies in the development and commercialisation of disruptive technologies. With its large network of capital providers and strategic partners it shares risk and crowds in market players.<\/p>\n<p>\n<b>About Invest-NL<\/b><\/p>\n<p>\nInvest-NL is the National Promotional Institution of the Netherlands, committed to driving a sustainable and innovative future. We accelerate and finance major societal transitions in the fields of Agrifood, Biobased &amp; Circular Economy, Deep Tech, Energy, and Life Sciences &amp; Health.<\/p>\n<p>\nAs a system player, we connect innovative entrepreneurs, financiers, knowledge institutions, and governments\u2014both in the Netherlands and abroad. We remove barriers, mobilise capital, and help develop emerging sectors. Through capital, expertise, and new financial instruments, we invest in tomorrow\u2019s solutions. Where the market hesitates, we take the first step. That is how we create impact.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Leyden Labs Media Contact<\/b><br \/>Megan Prock McGrath<br \/>\n<br \/>CTD Comms, LLC<br \/>\n<br \/>+1 978-800-7468<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;l&#x74;&#111;&#x3a;&#109;e&#x64;i&#x61;&#64;&#x6c;&#101;&#x79;&#100;e&#x6e;l&#x61;&#98;&#x73;&#46;&#x63;&#x6f;m\" rel=\"nofollow\" shape=\"rect\">&#x6d;&#x65;&#x64;&#x69;&#x61;&#x40;&#108;&#101;&#121;&#100;enla&#x62;&#x73;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p><b>Leyden Labs Investor Contact<\/b><br \/>Elizabeth Goodwin<br \/>\n<br \/>+1 781-460-1784<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x69;&#x6e;&#118;e&#x73;&#116;o&#x72;&#x73;&#64;l&#x65;&#x79;&#100;e&#x6e;&#108;&#97;&#x62;&#x73;&#46;c&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#x6e;&#x76;&#x65;&#x73;&#x74;&#x6f;&#x72;&#x73;&#x40;&#x6c;&#101;&#121;&#100;&#101;&#110;&#108;&#97;bs&#46;com<\/a><\/p>\n<p><b>European Innovation Council Fund Media Contact<\/b><br \/>Robert Schr\u00f6der<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x52;&#111;&#98;e&#x72;&#x74;&#x2e;&#115;&#99;h&#x72;&#x6f;&#x64;&#101;&#114;&#64;&#x65;&#x63;&#x2e;&#101;ur&#x6f;&#x70;&#x61;&#46;eu\" rel=\"nofollow\" shape=\"rect\">&#x52;&#x6f;&#98;e&#x72;&#x74;&#46;sc&#x68;&#x72;&#111;d&#x65;&#x72;&#64;&#101;c&#x2e;&#x65;&#117;r&#x6f;&#x70;&#97;&#46;e&#x75;<\/a><\/p>\n<p><b>Invest-NL Media Contact<\/b><br \/>Sanne Snieder<br \/>\n<br \/>+31 6 111 55 131<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x70;&#x65;r&#115;&#x40;i&#110;&#x76;e&#115;&#x74;-&#110;&#x6c;&#46;&#110;&#x6c;\" rel=\"nofollow\" shape=\"rect\">&#x70;&#101;r&#x73;&#64;i&#x6e;&#118;e&#x73;&#x74;&#45;&#x6e;&#x6c;&#46;n&#x6c;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dutch biotech Leyden Labs has raised a \u20ac30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company\u2019s other mucosal pipeline and platform activities. The support from the EIC Fund and Invest-NL helps strengthen Europe\u2019s preparedness against current and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61961","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Dutch biotech Leyden Labs has raised a \u20ac30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company\u2019s other mucosal pipeline and platform activities. The support from the EIC Fund and Invest-NL helps strengthen Europe\u2019s preparedness against current and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-02T05:02:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses\",\"datePublished\":\"2025-10-02T05:02:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/\"},\"wordCount\":1045,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251001741614\\\/en\\\/2596739\\\/22\\\/Leyden_Labs.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/\",\"name\":\"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251001741614\\\/en\\\/2596739\\\/22\\\/Leyden_Labs.jpg\",\"datePublished\":\"2025-10-02T05:02:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251001741614\\\/en\\\/2596739\\\/22\\\/Leyden_Labs.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251001741614\\\/en\\\/2596739\\\/22\\\/Leyden_Labs.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/","og_locale":"en_US","og_type":"article","og_title":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend","og_description":"Dutch biotech Leyden Labs has raised a \u20ac30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray, as well as the Company\u2019s other mucosal pipeline and platform activities. The support from the EIC Fund and Invest-NL helps strengthen Europe\u2019s preparedness against current and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-02T05:02:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses","datePublished":"2025-10-02T05:02:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/"},"wordCount":1045,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/","url":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/","name":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg","datePublished":"2025-10-02T05:02:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251001741614\/en\/2596739\/22\/Leyden_Labs.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/leyden-labs-secures-e30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Leyden Labs Secures \u20ac30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61961"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61961\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}